argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 41.97B |
| Revenue (ttm) | 3.14B |
| Net Income (ttm) | 1.31B |
| Shares Out | 61.20M |
| EPS (ttm) | 19.83 |
| PE Ratio | 34.58 |
| Forward PE | 31.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,588 |
| Average Volume | 80,225 |
| Open | 673.00 |
| Previous Close | 673.40 |
| Day's Range | 663.20 - 687.40 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.13 |
| RSI | 41.71 |
| Earnings Date | Mar 5, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity
The portfolio delivered a modest negative absolute return during Q4 but outpaced the Russell Midcap® Growth Index by several percentage points. IT was an area of strength during the quarter, led by ho...
Wedbush Reiterates Outperform Rating for ARGX with $1000 PT | ARGX Stock News
Wedbush Reiterates Outperform Rating for ARGX with $1000 PT | ARGX Stock News
Argenx (ARGX) Gains FDA Priority Review for Expanded Vyvgart Use
Argenx (ARGX) Gains FDA Priority Review for Expanded Vyvgart Use
Argenx bid for Vyvgart label expansion undergoes FDA priority review
FDA Prioritizes Argenx's sBLA for Vyvgart in Myasthenia Gravis Treatment
FDA Prioritizes Argenx's sBLA for Vyvgart in Myasthenia Gravis Treatment
Argenx's VYVGART Moves Closer To Expanded MG Use As FDA Grants Priority Review
(RTTNews) - Argenx SE (ARGX) has taken a significant step toward broadening the reach of VYVGART, after the U.S. FDA accepted the company's supplemental Biologics License Application for Priority Revi...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx SE at JPMorgan Healthcare Conference Transcript
argenx SE at JPMorgan Healthcare Conference Transcript
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-12. The following slide deck was published by argenx SE in conjunction with this event.
Argenx (ARGX) Projects Strong Revenue Growth for FY25
Argenx (ARGX) Projects Strong Revenue Growth for FY25
Argenx Preliminary 2025 Global Product Net Sales Up 90%
(RTTNews) - argenx (ARGX) announced preliminary global product net sales for full-year 2025 of approximately $4.15 billion, up 90% from prior year. Preliminary global product net sales for the fourth ...
argenx Highlights 2026 Strategic Priorities
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales
Citigroup Lowers Price Target for ARGX, Maintains Buy Rating | ARGX Stock News
Citigroup Lowers Price Target for ARGX, Maintains Buy Rating | ARGX Stock News
ARGX: Truist Securities Raises Price Target, Reaffirms Buy Rating | ARGX Stock News
ARGX: Truist Securities Raises Price Target, Reaffirms Buy Rating | ARGX Stock News
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
Oversold Conditions For argenx (ARGX)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Argenx (ARGX) Announces Leadership Transition with New CEO Appointment
Argenx (ARGX) Announces Leadership Transition with New CEO Appointment
Argenx (ARGX) Announces Leadership Transition
Argenx (ARGX) Announces Leadership Transition
argenx Announces Leadership Transition Marking Next Evolution of Growth
Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 9.76% on an annualized basis producing an average annual return of 23.04%. Currently, argenx has a market capitalization of ...
5 Top Stocks With High 2026 Earnings Growth Targets
The S&P 500 experienced sharp swings in 2025 due to shifts in trade policy, AI speculation, and rate cuts, while corporate profits remained resilient. Broader AI adoption and steady economic growth ar...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Argenx (ARGX) Downgraded by Baird Amid Valuation Concerns
Argenx (ARGX) Downgraded by Baird Amid Valuation Concerns